Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA

The U.S. Food and Drug Administration (FDA) has issued a guidance document titled “Computer Software Assurance for Production and Quality System Software,” aimed at modernizing the approach to software validation within the medical device industry. This guidance provides recommendations on risk-based assurance activities for computer software used in production and quality systems, aligning with FDA’s Quality System Regulation (QSR) and international standards.

Key Takeaways from the Guidance

1. Risk-Based Approach to Software Assurance:
   • The guidance shifts from a traditional validation approach to a risk-based framework, emphasizing activities that provide confidence in software performance while focusing on patient safety, product quality, and data integrity.
   • It categorizes software based on its impact on medical device safety and quality rather than treating all software with the same level of scrutiny.
2. Differentiation Between Software Types:
   • Process Software: Used in manufacturing, testing, or inspecting medical devices.
   • Quality System Software: Supports compliance with regulatory requirements such as electronic records and signatures.
   • The guidance excludes software embedded in medical devices, which remains subject to separate validation requirements.
3. Types of Assurance Activities Recommended:
   • Unscripted testing (ad-hoc, exploratory testing)
   • Scripted testing (formalized protocols)
   • Supplier-provided documentation and verification activities
   • Automated testing tools for increased efficiency
4. Reduction of Burdensome Documentation:
   • The guidance encourages manufacturers to streamline documentation by focusing on critical quality attributes and risk-based justification.
   • Instead of extensive documentation, manufacturers can leverage records of successful software execution and risk assessments.
5. Alignment with Existing Regulations:
   • The recommendations are consistent with 21 CFR Part 820 (Quality System Regulation) and ISO 13485:2016 standards.
   • It complements the FDA’s broader initiative to harmonize quality management systems with international standards.

Benefits of the New Approach

• Increased Flexibility: Allows manufacturers to apply different software assurance techniques depending on risk levels.
• Efficiency Gains: Reduces unnecessary validation steps, thereby lowering costs and saving time.
• Enhanced Innovation: Supports the adoption of emerging technologies, such as artificial intelligence and automated systems, by providing a clearer regulatory pathway.

Conclusion

The FDA’s guidance on Computer Software Assurance represents a significant step toward modernizing software validation practices in the medical device industry. By shifting to a risk-based approach, the guidance fosters efficiency, innovation, and regulatory compliance while maintaining high standards for patient safety and product quality. Manufacturers are encouraged to integrate these recommendations into their quality systems to optimize their software validation processes effectively.

Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA – by Shudarsana Company